4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 64 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83,000 | +40.7% | 6,485 | +101.2% | 0.00% | – |
| Q2 2023 | $59,000 | +96.7% | 3,223 | +84.8% | 0.00% | – |
| Q1 2023 | $30,000 | -61.5% | 1,744 | -49.8% | 0.00% | – |
| Q4 2022 | $78,000 | +2500.0% | 3,471 | +697.9% | 0.00% | – |
| Q3 2022 | $3,000 | +200.0% | 435 | +108.1% | 0.00% | – |
| Q2 2022 | $1,000 | -96.3% | 209 | -88.1% | 0.00% | – |
| Q1 2022 | $27,000 | -77.1% | 1,756 | -67.4% | 0.00% | – |
| Q4 2021 | $118,000 | +87.3% | 5,382 | +129.6% | 0.00% | – |
| Q3 2021 | $63,000 | +293.8% | 2,344 | +247.3% | 0.00% | – |
| Q2 2021 | $16,000 | -48.4% | 675 | -5.3% | 0.00% | – |
| Q1 2021 | $31,000 | – | 713 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |